Solid Tumor Targeting CAR-T Development Services with ON Switch

ON switch systems provide precise pharmacological control over CAR-T cell activity, enhancing safety and adaptability in solid tumor immunotherapy. Creative Biolabs' Solid Tumor Targeting CAR-T Development Services with ON Switch integrate these advanced regulatory technologies into tailored CAR constructs designed for complex tumor microenvironments. By combining modular targeting strategies with comprehensive quality validation, we significantly mitigate on-target/off-tumor risks and cytokine release syndrome (CRS), while ensuring consistent product performance.

Introduction

While CAR-T therapy has demonstrated remarkable efficacy in hematological malignancies, its application against solid tumors remains challenged by safety concerns, such as on-target/off-tumor toxicity and CRS. "ON Switch" technologies, exemplified by chemically inducible dimerization (CID) and tetracycline-regulated systems, enable real-time, reversible control over CAR-T activity through the administration of small-molecule drugs. These switch systems not only offer precise safety interventions to mitigate off-target effects and CRS risks but also enhance the controllability and adaptability of CAR-T cells within the complex tumor microenvironment, thereby significantly expanding the therapeutic window and clinical potential of CAR-T immunotherapy.

Fig.1 Design and cloning strategies of the tetracycline-regulated system.¹

Solid Tumor Targeting CAR-T Development Services with ON Switch at Creative Biolabs

Creative Biolabs' Solid Tumor Targeting CAR-T Development Services integrates advanced ON-switch systems such as CID and Tet to enable real-time, dose-dependent control over T cell activity. Our platform combines modular targeting design with comprehensive quality validation, delivering not only enhanced safety against on-target/off-tumor toxicity and CRS, but also comprehensive data packages to streamline regulatory approval.

Service Packages

We offer modular ON-switch CAR-T platforms, including CID and Tet systems, to provide tailored solutions for precise temporal and dose-dependent control of T cell activity against solid tumors.

Our Service Process

Required Starting Materials:

• Target Antigen Sequence.
• Patient T cell Source/PBMCs.
• Desired CAR Structure/ScFv Clone.

Key Steps:

Final Deliverables:

• Finalized Vector Construct.
• Comprehensive Quality Report.
• Function Assays Data.

Key Advantages

• Custom CAR Design & Engineering: We provide tailored genetic engineering of CAR constructs by integrating your selected ScFv clone with specialized ON switch systems, enabling precise pharmacological control of T cell activity. Optimized codon usage ensures high and consistent CAR expression.
• Modular Targeting Platforms: Our custom modular CAR systems, such as UniCAR, are designed and functionally validated to overcome solid tumor antigen heterogeneity and mitigate antigen escape risks, thereby enabling a highly adaptable and future-proof targeting strategy.
• Comprehensive Data Packages: We deliver a complete data suite, including quality reports and reversible safety/efficacy profiles, specifically curated to support and expedite your regulatory submission process.

FAQs

Why Choose Us?

At Creative Biolabs, we deliver precision and safety in solid tumor CAR-T development. Our ON Switch technology enables real-time, reversible control over T-cell activity, mitigating CRS and neurotoxicity risks. Supported by advanced quality control and modular system expertise, we ensure consistent, homogenous products with clear regulatory pathways. Partner with us to advance controllable, next-generation cell therapies with confidence.

Customer Reviews

"By employing Creative Biolabs' Solid Tumor Targeting CAR-T Development Services equipped with the ON Switch, we significantly accelerated the validation of our TPD-based switch system. Their platform delivered reliable data that clearly illustrated degradation efficiency and functional recovery, offering critical experimental evidence to support our mechanistic conclusions." Dr. A***da.

"The quality report from Creative Biolabs played a pivotal role in characterizing the heterogeneity of our final CAR-T product. It enabled the identification of a low-expression subpopulation, which was promptly optimized to ensure the production of a consistently potent therapeutic dose." J. Kobn.

"To mitigate translational risks such as CRS, we leveraged Creative Biolabs' ON-switch system, which utilizes the drug lenalidomide. The resulting CAR-T construct exhibited stable and reversible activity in humanized models, substantially lowering preclinical safety concerns and supporting its potential for clinical application." Prof. Sna Le.

How to Contact Us?

Creative Biolabs serves as your trusted strategic partner, committed to advancing the next generation of CAR-T therapies for solid tumors by addressing key challenges in safety, efficacy, and controllability. Leveraging advanced molecular switch technology, we help clear critical development hurdles and significantly mitigate toxicity risks through programmable activity control.

Inquire now to discuss your project and learn more.

Reference

1. Ingole, Kishor D et al. "Tetracycline-controlled (TetON) gene expression system for the smut fungus Ustilago maydis." Frontiers in fungal biology vol. 3 1029114. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/ffunb.2022.1029114.